Skip to content
Advertisement

Cheryl K. Chumley

Cheryl K. Chumley

Cheryl Chumley is online opinion editor, commentary writer and host of the “Bold and Blunt” podcast for The Washington Times, and a frequent media guest and public speaker. She is the author of several books, the latest titled, “Lockdown: The Socialist Plan To Take Away Your Freedom,” and “Socialists Don’t Sleep: Christians Must Rise or America Will Fall.” Email her at cchumley@washingtontimes.com. 

Latest "Bold & Blunt" Podcast Episodes

Columns by Cheryl K. Chumley

Russian President Vladimir Putin meets with Russian entrepreneurs while visiting a SIBUR Holding petrochemical plant in Voronezh, 534 km (334 miles) south of Moscow, Russia, Thursday, May 23, 2013. (AP Photo/RIA-Novosti, Mikhail Klimentyev, Presidential Press Service)

Russia rocked by magnitude 8 earthquake

Russia's Far East region was rocked on Friday by a powerful earthquake that geologists put between 8.0 and 8.2 on the Richter scale. Published May 24, 2013

Good Samaritan’s car stolen by victim he helps — and it gets worse

A Colorado man who stopped to help an accident victim who had rolled his car on the highway and was trapped inside got a real life lesson in the saying, 'no good deed goes unpunished.' Once the victim was freed, he stole the Good Samaritan's truck and fled. Published May 22, 2013

Pope Francis leaves at the end of his weekly general audience in St. Peter's Square at the Vatican on Wednesday, May 22, 2013. (AP Photo/Alessandra Tarantino)

Pope Francis attacks ‘savage capitalism’ in call for charity

Pope Francis, in a blistering attack on capitalism, said followers of the faith ought to bolster their charitable outreach and dampen their materialist pursuits. He made his comments while visiting a food kitchen on Tuesday. Published May 22, 2013

The London headquarters of the pharmaceutical company GlaxoSmithKline PLC are pictured in 2006. (Associated Press)

U.S. forges $200 million antibiotic deal with GlaxoSmithKline

The federal government has signed a $200 million deal with GlaxoSmithKline to develop powerful antibiotics that can combat bioterrorism and overcome resistance issues that have made some prescriptions worthless in recent years. Published May 22, 2013